Q BioMed Inc (OTCQB: QBIO) Featured in April Issue
of PharmaVOICE Magazine
Getting Past the
"Pharma Bro"; How Smaller Biotechs Continue to Strive for the
Well-Being of Patients
NEW
YORK - April 5, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology
acceleration company reports the Company's CEO was featured in an interview in
the April issue of PharmaVOICE magazine.
PharmaVOICE
magazine, reaching more than 41,000 BPA-qualified life-sciences executives, is
the forum that allows business leaders to engage in a candid dialogue on the
challenges and trends impacting the industry.
CEO,
Denis Corin talks to PharmaVOICE magazine about Martin Shkreli's actions, drug
prices and how he and his company are approaching the issues facing biotech
innovators now and in the future.
Excerpt:
PV:
Martin Shkreli's decision to increase the price of an inexpensive drug from
$13.50 to $750 created a media uproar, reigniting negative attitudes toward the
life-sciences industry. Is there anything positive that can come from this?
Corin:
It's created a talking point, and it's provided more focus on the
pharmaceutical industry and biotechnology to a degree. His approach and his
attitude is just not consistent with the majority of people in pharma
development and certainly not true of the younger, smaller biotech companies
that are truly the innovators and the driving force behind a lot of new drug
creation. This attitude is not reflective of the way many of us do things or
the reasons why we do what we do.
Quite
candidly, in the smaller-cap biotech space, companies are being run on
shoestring budgets, and we're out there every day raising dollars wherever we can
to develop these assets.
The
way Shkreli's positioned this - gouging people on this one particular drug - is
not representative of what's going on in the biotech innovation space. Every
biotech CEO has to have some kind of philanthropy or philanthropic outlook on
life when it comes to what he or she is doing. We have to be doing it for the
ultimate good of the patients and their families and if we can do that, all
things will fall into place and the company will do well. There will be ample
profit for the shareholders and enough money to feed back into innovation and
drug development.
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and
development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets,
strategic resources, developmental support, and expansion capital to ensure
they meet their developmental potential enabling them to provide products to patients
in need.
Forward-Looking
Statements:
This
press release may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements
are based on management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are: risks related to our
growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Sign up for the
free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
No comments:
Post a Comment